NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas
Priyanka D. Sehgal, Ammar S. Naqvi, Makenna Higgins, Jia‐Geng Liu, Kyra Harvey, Julien Jarroux, Tae Woo Kim, Berk Mankaliye, Pamela Mishra, Grace Watterson, Justyn Fine, Jacinta Davis, Katharina E. Hayer, Annette Castro, Adanna Mogbo, , Andrei Thomas‐Tikhonenko
The paper identifies a NRCAM proteoform with skipped microexons as a targetable surface antigen in pHGG and demonstrates its utility in immunotherapy.
Cell Reports · Aug 1, 2025Peer-reviewedCancer Biology